Evidence map›Paper›PMID 36370253›Full record

ReviewPurinergic signalling2023

Purinergic signaling: a potential therapeutic target for ischemic stroke.

Lu Wang, Ying-Jie Li, Xu Yang, Bo Yang, Xin Zhang, Jing Zhang, Qi Zhang, Xu-Dong Cheng, Jian-Hong Wang, Neng-Wei Yu

Open access · greenAbstract readReview
In one paragraph

Review in Purinergic signalling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. From danger to resolution: targeting purinergic signaling in CNS diseases.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Review
  3. Review
  4. Longitudinal imaging evaluation of the inflammatory role of purinergic AJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Article
  5. Article
  6. Review
  7. The Study of the Protection Mechanism of Calycosin-7-Molecules (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Targeting Cysteine Oxidation in Thrombotic Disorders.Antioxidants (Basel, Switzerland) · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Lu Wang *Department of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Ying-Jie Li *Department of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Xu YangDepartment of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Bo YangDepartment of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Xin ZhangDepartment of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Jing ZhangDepartment of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Qi ZhangDepartment of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Xu-Dong ChengDepartment of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Jian-Hong WangDepartment of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China.
Neng-Wei YuDepartment of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, 610072, China. 18981838652@126.com.
University of Electronic Science and Technology of China · CNSichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogenesis of ischemic stroke is mainly characterized by thrombosis and neuroinflammation. Purinergic signaling pathway constitutes adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), and adenosine (ADO). ATP is hydrolyzed to ADP and then to AMP by extracellular nucleotidase CD39; AMP is subsequently converted to adenosine by CD73. All these nucleotides and nucleosides act on purinergic receptors protecting against thrombosis and inhibit inflammation. In addition, many physical methods have been found to play a neuroprotective role through purinergic signaling. This review mainly introduces the role and potential mechanism of purinergic signalings in the treatment of ischemic stroke, so as to provide reference for seeking new treatment methods for stroke.

Indexed as

Ischemic StrokeThrombosis5'-NucleotidaseAdenosineAdenosine DiphosphateAdenosine MonophosphateAdenosine TriphosphateAntigens, CDApyraseHumansSignal Transduction5'-NucleotidaseAdenosineAdenosine DiphosphateAdenosine MonophosphateAdenosine TriphosphateAntigens, CDApyraseAdenosineCD39EctonucleotidaseIschemic strokePurinergic signaling

Identifiers

PMID36370253
PMCPMC9984595
OpenAlexW4308834418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.